Another way to look at it is this…… assuming $90k cost of...

Another way to look at it is this…… assuming $90k cost of treatment, at about 67% margin, for profit of $60k per treatment, Prima would only have to treat 260 patients per year to justify the current share price / market cap….. 260 x $60k x P/E of 12x = $187 Mil

Simplistic I know, ignores dilution to commercialisation, risk of not making it to commercialisation and time to commercialisation, but makes for interesting numbers when you consider that the size of the market we are specifically targeting is currently 22,000 pa and growing (in the US & EU alone), and if ICS data comes out well than the target market could increase dramatically

Makes me feel pretty comfortable with my entry price